178 related articles for article (PubMed ID: 34396513)
1. Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group.
Eichenauer DA; Bühnen I; Kreissl S; Goergen H; Fuchs M; von Tresckow B; Rosenwald A; Klapper W; Hansmann ML; Möller P; Bernd HW; Feller AC; Engert A; Borchmann P; Hartmann S
Br J Haematol; 2022 Jan; 196(1):99-104. PubMed ID: 34396513
[TBL] [Abstract][Full Text] [Related]
2. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
4. PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.
Eichenauer DA; Kreissl S; Bühnen I; Baues C; Kobe C; van Heek L; Goergen H; Fuchs M; Hartmann S; von Tresckow B; Engert A; Borchmann P
Ann Oncol; 2021 Jun; 32(6):807-810. PubMed ID: 33667668
[No Abstract] [Full Text] [Related]
5. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
6. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
[TBL] [Abstract][Full Text] [Related]
7. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
8. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
9. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Engert A; Haverkamp H; Kobe C; Markova J; Renner C; Ho A; Zijlstra J; Král Z; Fuchs M; Hallek M; Kanz L; Döhner H; Dörken B; Engel N; Topp M; Klutmann S; Amthauer H; Bockisch A; Kluge R; Kratochwil C; Schober O; Greil R; Andreesen R; Kneba M; Pfreundschuh M; Stein H; Eich HT; Müller RP; Dietlein M; Borchmann P; Diehl V; ; ;
Lancet; 2012 May; 379(9828):1791-9. PubMed ID: 22480758
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
12. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
13. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann P; Goergen H; Kobe C; Lohri A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Hüttmann A; Dierlamm J; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Schmitz N; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Kuhnert G; Diehl V; Dietlein M; Engert A
Lancet; 2017 Dec; 390(10114):2790-2802. PubMed ID: 29061295
[TBL] [Abstract][Full Text] [Related]
14. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
15. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
Sasse S; Goergen H; Plütschow A; Böll B; Eichenauer DA; Fuchs M; Behringer K; Zijlstra JM; Greil R; Markova J; Topp MS; Meissner J; Neubauer A; Baues C; Engert A; Borchmann P; von Tresckow B
J Clin Oncol; 2018 Sep; 36(25):2603-2611. PubMed ID: 29989855
[TBL] [Abstract][Full Text] [Related]
17. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.
Gallamini A; Tarella C; Viviani S; Rossi A; Patti C; Mulé A; Picardi M; Romano A; Cantonetti M; La Nasa G; Trentin L; Bolis S; Rapezzi D; Battistini R; Gottardi D; Gavarotti P; Corradini P; Cimminiello M; Schiavotto C; Parvis G; Zanotti R; Gini G; Ferreri AJM; Viero P; Miglino M; Billio A; Avigdor A; Biggi A; Fallanca F; Ficola U; Gregianin M; Chiaravalloti A; Prosperini G; Bergesio F; Chauvie S; Pavoni C; Gianni AM; Rambaldi A
J Clin Oncol; 2018 Feb; 36(5):454-462. PubMed ID: 29360414
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
20. PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP.
Deau B; Franchi P; Briere J; Ohnona J; Tamburini J; Thieblemont C; Brice P
Br J Haematol; 2015 Jul; 170(2):278-81. PubMed ID: 25580881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
